Document is current
Any future updates will be listed below
-
Authors
van Dam, Cornelis Jan https://orcid.org/0000-0002-7087-1528
van Velzen, Monique
Kramers, Cornelis
Schellekens, Arnt https://orcid.org/0000-0002-7715-5209
Olofsen, Erik
Niesters, Marieke
Dahan, Albert https://orcid.org/0000-0003-3161-3945
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWA.1160.18.300)
Bdrocan BV
- License Information
-
More Information
Article History
Received: 11 October 2022
Accepted: 5 January 2023
First Online: 27 January 2023
Declarations
:
: Approval of the protocol has been obtained from the Medical Research and Ethics Committee (MREC) Leiden-Den-Haag-Delft (Leiden University Medical Center, Albinusdreef 2, 2333 RC Leiden, the Netherlands); identifier P19.050, on July 17, 2019. Written, informed consent to participate will be obtained from all participants.
: All authors give consent for publication provided that they agree with the contents of the paper and their contributions are acknowledged. The sponsors have no influence on the publications process. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are available from the corresponding author on request.
: AD received consulting fees and is member of the scientific advisory board of Enalare Therapeutics (USA) and member of the scientific board of MyCB1 Group BV (the Netherlands). AD received grants from ZonMW, the Hague (the Netherlands), and an award from the US Food and Drug Administration (USA). All other authors declare that they have no competing interests.
